Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands

The anticancer properties of two new fluorescent platinum(II) compounds, cis-[Pt(A9opy)Cl₂] and cis-[Pt(A9pyp)(dmso)Cl₂] are described. These compounds are highly active against several human tumor cell lines, including human ovarian carcinoma sensitive and cisplatin-resistant cell lines (A2780 and A2780R). To study the cellular processing of these new compounds, a series of in vitro studies have been performed, including the investigation of intracellular platinum accumulation and DNA-platination experiments in A2780 and A2780R cells. Compared to cisplatin, both compounds are accumulated highly in both sensitive and resistant cell lines, and more platinum has been found to bind to the nuclear DNA. Interestingly, cis-[Pt(A9opy)Cl₂] shows high accumulation and DNA adduct formation in the resistant cell line A2780R, as compared to the sensitive counterpart A2780 cell line. This suggests that cis-[Pt(A9opy)Cl₂] is able to overcome some of the well-known resistance mechanisms in this cell line, such as decreased cellular uptake and increased DNA repair.     

Novel 4,4′-diether-2,2′-bipyridine cisplatin analogues are more effective than cisplatin at inducing apoptosis in cancer cell lines

The synthesis and characterization of dichloro(4,4′-bis[methoxy]-2,2′-bipyridine)platinum (1) and dichloro(4,4′-bis[3-methoxy-n-propyl]-2,2′-bipyridine)platinum (2) are described. As analogues to CDDP, these 4,4′-disubstituted 2,2′-bipyridine complexes exhibit decreased EC₅₀ values of 10–100 times in cancer cell lines of the lung, prostate, and melanoma with several combinations of complex and cell line less than 10 μM. Flow cytometry data indicate ‘blocks’ of MDA-MD-435 cycle by 1 (G2/M) and 2 (S). Observed cell survival trends in the presence of 1, 2 under ionizing radiation mimic those of CDDP. Preliminary structure activity relationships are discussed for the 4,4′-substitutions made on the bipyridine ring.     

Synthesis and anticancer activity of dichloroplatinum(II) complexes of podophyllotoxin

A series of dichloroplatinum(II) complexes of podophyllotoxin (PPT) were prepared, and their cytotoxicity against sensitive (A-549, HeLa, HCT-8, Hep-G2, K562) and resistant (ADM/K562) cell lines were evaluated. Complex cis-[4α-O-(2″,3″-diaminopropanoyl)-podophyllotoxin] dichloride platinum(II) (12) displayed most potent cytotoxicity with IC₅₀ value in the range 0.071–2.98 μM. Complex 12 induces cell cycle arrest in the G₂/M phase, and inhibits the formation of microtubules in HeLa cells. Furthermore, this complex exhibits potent DNA cleavage capabilities.     

Dichloro(6-aminoethylaminopurine)platinum(II) and its hydroxy analogues: Synthesis and preliminary evaluation

The synthesis, chemical characterization and functional evaluation are reported for dichloro(6-aminoethylaminopurine)platinum(II) and dichloro(6-hydroxyethylaminopurine)platinum(II) and dichloro(6-hydroxyethylamethylaminopurine)platinum(II) (i.e. Pt(6-AEAP), Pt(6-HEAP) and Pt(6-MHEAP) new complexes of platinum(II). Certain reaction conditions favored the formation of the tripurine platinum complex, but the monopurine complex could be obtained either by hydrolysis of the tripurine or by reacting at reduced temperature and concentration. Although neither compound was as effective as cis-diamminedichloroplatinum(II) (i.e. DDP) at reducing tumor cell viability or proliferation, both were associated with much less renal toxicity than DDP in the mouse kidney (i.e. Pt(6-AEAP):～20 × less; Pt(6-MHEAP): ～100 × less).     

Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand

A new anticancer-active platinum(II) compound [Pt(A9pyp)(dmso)(cbdca)], containing the E-1-(9-anthryl)-3-(2-pyridyl)-2-propenone ligand (abbreviated as A9pyp) has been synthesized by the replacement of the anionic chloride ligands in cis-[Pt(A9pyp)(dmso)Cl₂] by the dianionic chelating cyclobutanedicarboxylate ligand (abbreviated as cbdca). The in vitro relevance of the leaving group of these new platinum(II) compounds has been investigated. Measurements of the time-dependent intracellular accumulation of both compounds in human ovarian carcinoma cell lines show that the leaving group affects their cellular uptake. In addition, the leaving group also influences DNA platination, and, therefore, has an effect on the biological activity against a pair of human ovarian carcinoma cell lines, i.e. sensitive and resistant to cisplatin.     

Design, synthesis and in vitro cytotoxicity of novel dinuclear platinum(II) complexes

Five dinuclear platinum(II) complexes with a novel chiral ligand, 2-(((1R,2R)-2-aminocyclohexylamino)methyl)phenol (HL), were designed, prepared and spectrally characterized. In vitro cytotoxicity of all the resulting platinum(II) compounds was evaluated against human HEPG-2, A549 and HCT-116 cell lines, respectively. Results indicated that all compounds showed positive biological activity. Particularly, compound D4 has lower IC₅₀ values than carboplatin toward HEPG-2 and A549, while compound D5 shows better activity than carboplatin against A549.     

Synthesis,characterization and DNA binding studies of platinum(II) complexes with benzimidazole derivative ligands

The aim of this study was to synthesize and evaluate plasmid DNA interaction of new platinum(II) complexes with some 2-substituted benzimidazole derivatives as carrier ligands which may have potent anticancer activity and low toxicity. Twelve benzimidazole derivatives carrying indole, 2-/or 3-/or 4-methoxyphenyl, 4-methylphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 4-methoxybenzyl, 3,4,5-trimethoxybenzyl, 3,4,5-trimethoxystyryl, 3,4,5-trimethoxybenzylthio or dimethylamino ethyl groups in their position 2 and twelve platinum(II) complexes with these carrier ligands were synthesized. The chemical structure of the platinum complexes have been characterized by their elemental analysis and FIR, ¹H NMR and mass spectra and their ¹H NMR and FIR spectra were interpreted by comparison with those of the ligands. The interaction of all the ligands and their complexes with plasmid DNA and their restriction endonuclease reactions by BamHI and HindIII enzymes were studied by agarose gel electrophoresis. It was determined that complex 1 [dichloro-di(2-(1H-indole-3-yl)benzimidazole)platinum(II)·2H₂O] has stronger interaction than carboplatin and complex 10 [dichloro-di(2-(3,4,5-trimethoxystyryl)benzimidazole)platinum(II)·2H₂O] has stronger interaction than both carboplatin and cisplatin with plasmid DNA.     

Four new steroidal glycosides from Solanum torvum and their cytotoxic activities

Two novel C-22 steroidal lactone saponins, namely solanolactosides A, B (1, 2) and two new spirostanol glycosides, namely torvosides M, N (3, 4) were isolated from ethanol extract of aerial parts of Solanum torvum. Their structures were characterized as solanolide 6-O-[α-l-rhamnopyranosyl-(1 → 3)-O-β-d-quinovopyranoside] (1), solanolide 6-O-[β-d-xylopyranosyl-(1 → 3)-O-β-d-quinovopyranoside] (2), yamogenin 3-O-[β-d-glucopyranosyl-(1 → 6)-O-β-d-glucopyranoside] (3) and neochlorogenin 3-O-[β-d-glucopyranosyl-(1 → 6)-O-β-d-glucopyranoside] (4) on the basis of spectroscopic analysis. The cytotoxicities of the saponins (1-4) were evaluated in vitro against a panel of human cancer cell lines. Compounds 3 and 4 showed significant cytotoxic activity with the cell lines.     

Antitumor steroidal-cis-platinum(II)-o-catecholato conjugates: preliminary evaluation on breast cancer MCF-7 cells

Six new steroidal-cis-platinum(II)-o-catecholato complexes (5–9 and 15) were prepared by treatment of either [4-(2-aminoethyl)1,2-benzenediolato(2-)-O, O′]-bis(triphenylphosphine)platinum(II) or [3,4-dihydroxybenzenepropionic acid (2-)-O³, O⁴]-bis-(triphenylphosphine)platinum(II) with appropriate functionalized steroids. The biological effect of the air-stable conjugates on a human breast tumor cell line, MCF-7, was compared with that of cis-dichloro-diaminoplatinum(II) (cis-DDP). The activity of the new compounds proved to be of the same order of magnitude as cis-DDP.     

Biological effect of mono- and dinuclear alkylamine platinum(II) compounds on human lymphoma cells

The effects of the mononuclear chloro[meso-1,2-bis(4-fluorophenyl)ethylenediamine][hexylamine]platinum(II) chloride HACl and the dinuclear di[meso-1,2-bis(4-fluorophenyl)ethylenediamine]dichloro(mu-1,n-diaminoalkane-N:N')diplatinum(II)dichloride complexes DAHCl (alkane:hexane), DANCl (alkane:nonane) and DADCl (alkane:dodecane) with different alkyl chain length (n) were investigated on non-Hodgkin's lymphoma (NHL) and chronic myeloid leukemia (CML) cell lines. All compounds showed an antiproliferative effect on the NHL cell lines RAJI and U-937 accompanied in the case of DANCl, DAHCl, HACl and cisplatin by an increase in apoptosis. The growth of another NHL (JEKO-1) and one CML cell line (K-562) was decreased only by cisplatin. In contrast to HACl, DAHCl, DANCl and cisplatin, DADCl induced necrosis, suggesting toxicity because cell viability decreased. Similar effects were observed when bone marrow-derived lymphoma cells from a patient with high-grade B-NHL were incubated with the platinum complexes.     

Synthesis and structural characterization of two new copper(II) complexes with thiazoline derivative ligands: Influence of the coordination on the phagocytic activity of human neutrophils

Two new copper(II) complexes dichloro[2-(3,4-dichlorophenyl)imine-κN-(2-thiazolin-κN-2-yl)thiazolidine]copper(II) [CuCl₂(TdTn)] (1) and dichloro[2-(3,4-dichlorophenyl)imine-κN-(2-thiazolin-κN-2-yl)tetrahydrothiazine]copper(II) [CuCl₂(TzTn)] (2) were synthesized, then characterized by elemental analysis, UV-Vis-NIR diffuse reflectance, electron paramagnetic resonance (EPR) spectroscopy, magnetic susceptibility, infrared spectroscopy, and finally their crystal structures determined by X-ray diffractometry. The structural determination of [CuCl₂(TzTn)] (2) was made by conventional single-crystal diffractometry, whereas the procedure followed to resolve the crystal structure of [CuCl₂(TdTn)] (1) by means powder diffractometry using direct-space methods with a ‘Monte-Carlo/parallel tempering’ search algorithm. A final refinement of the crystal structure was performed using the Rietveld method. It was found that the environment around the copper(II) ion for both complexes can be described as having a distorted tetrahedral geometry, with the metallic atom coordinated with two chlorides, one imine nitrogen and one thiazoline nitrogen. The biological activity of the complexes, inorganic salt and their ligands has been evaluated by examining their phagocytic activity on human neutrophils. This activity enhances in the case of the samples treated with [CuCl₂(TdTn)] (1) and [CuCl₂(TzTn)] (2) with respect to the ones to which CuCl₂, TdTn or TzTn was added.     

Synthesis and structure of platinum(II) complexes containing an asymmetric chelating diamine 2-morpholinoethylamine as the carrier

A series of novel platinum(II) complexes involving an asymmetric chelating diamine 2-morpholinoethylamine (MPEA) as the carrier, cis-[Pt(MPEA)X₂] (X₂ = 2Cl⁻, oxalate, malonate, 1,1-cyclobutanedicarboxylate (CBDCA), 3-hydroxy-1,1-cyclobutanedicarboxylate (HO-CBDCA)), have been synthesized and characterized by elemental analysis and spectroscopic data along with X-ray crystal structure for a representative complex cis-[Pt(MPEA) (CBDCA)]. The Pt(II) is in a square planar environment and is coordinated by a chelating CBDCA and MPEA in cis position. The complexes with dicarboxylate are quite soluble (>25 mg/ml) and stable in water. The cytotoxicity of the complexes has been assessed in the human lung cancer cell lines A549 and A549/ATCC. One complex, cis-[Pt(MPEA)Cl₂], is more active than carboplatin against both the sensitive and resistant cells, and has less cross-resistance with cisplatin.     

New trans dichloro (triphenylphosphine)platinum(II) complexes containing N-(butyl),N-(arylmethyl)amino ligands: Synthesis,cytotoxicity and mechanism of action

Some new platinum(II) complexes have been prepared, of general formula trans-[PtCl₂(PPh₃){NH(Bu)CH₂Ar}], where the dimension of the Ar residue in the secondary amines has been varied from small phenyl to large pyrenyl group. The obtained complexes, tested in vitro towards a panel of human tumor cell lines showed an interesting antiproliferative effect on both cisplatin-sensitive and -resistant cells. For the most cytotoxic derivative 2a the investigation on the mechanism of action highlighted the ability to induce apoptosis on resistant cells and interestingly, to inhibit the catalytic activity of topoisomerase II.     

A fluorine containing bipyridine cisplatin analog is more effective than cisplatin at inducing apoptosis in cancer cell lines

Novel cisplatin analogs dichloro[4,4′-bis(4,4,4-trifluorobutyl)-2,2′-bipyridine]platinum (1) and fac-tricarbonylchloro[4,4′-bis(4,4,4-trifluorobutyl)-2,2′-bipyridine]rhenium (3) were synthesized and evaluated for their cytotoxicity. While 3 was not cytotoxic, 1 was 14 to 125 times more lethal than cisplatin in breast, prostate, and lung cancer cell lines. Compound 1 was able to induce apoptosis and the presence of the platinum atom was essential to its function as a cytotoxin.     

Platinum(II) imidazo[4,5-f]-1,10-phenanthroline chloride and thiolate complexes: Synthesis and crystal structures

The planar aromatic imidazo[4,5-f]-1,10-phenanthroline ligands have been used to prepare platinum(II) chloride and thiolate complexes. The X-ray structures of two thiolate compounds are reported, which show column-like packing in the solid state due to intermolecular aromatic π-π interactions. The compounds absorb moderately in the visible region, owing to {charge-transfer-to-diimine} electronic transition.     

Synthesis and proapoptotic activity of oleanolic acid derived amides

Thirty-one different 3-O-acetyl-OA derived amides have been prepared and screened for their cytotoxic activity. In the SRB assays nearly all the carboxamides displayed good cytotoxicity in the low μM range for several human tumor cell lines. Low EC₅₀ values were obtained especially for the picolinylamides 14–16, for a N-[2-(dimethylamino)-ethyl] derivative 27 and a N-[2-(pyrrolinyl)-ethyl] carboxamide 28. These compounds were submitted to an extensive biological testing and proved compound 15 to act mainly by an arrest of the tumor cells in the S phase of the cell cycle. Cell death occurred by autophagy while compounds 27 and 28 triggered apoptosis.     

Novel synthesis of methyl 4,6-O-benzylidenespiro[2-deoxy-α-d-arabino-hexopyranoside-2,2′-imidazolidine] and its homologue and sugar-γ-butyrolactam derivatives from methyl 4,6-O-benzylidene-α-d-arabino-hexopyranosid-2-ulose

Novel methyl 4,6-O-benzylidenespiro[2-deoxy-α-d-arabino-hexopyranoside-2,2′-imidazolidine] and its homologue methyl 4,6-O-benzylidene-3′,4′,5′,6′-tetrahydro-1′H-spiro[2-deoxy-α-d-arabino-hexopyranoside-2,2′-pyrimidine] have been synthesized in good yields by reaction of methyl 4,6-O-benzylidene-α-d-arabino-hexopyranosid-2-ulose with 1,2-diaminoethane and 1,3-diaminopropane. The results are completely different from the reaction with arylamines or alkylamines. One-pot synthesis of novel (E)-methyl 4-[hydroxy (methoxy)methylene]-5-oxo-1-alkyl-(4,6-O-benzylidene-2-deoxy-α-d-glucopyranosido)[3,2-b]pyrrolidines has been achieved by the reaction of alkylamines with the butenolide-containing sugar, derived from the aldol condensation of methyl 4,6-O-benzylidene-α-d-arabino-hexopyranosid-2-ulose with diethyl malonate. These sugar-γ-butyrolactam derivatives are potential GABA receptor ligands.     

Novel C,N-chelate platinum(II) antitumor complexes bearing a lipophilic ethisterone pendant

The novel steroidal carrier ligand 17-α-[4′-ethynyl-dimethylbenzylamine]-17-β-testosterone (ET-dmba 1) and the steroid — C,N-chelate platinum(II) derivatives [Pt(ET-dmba)Cl(L)] (L = DMSO (2) and PTA (3; PTA = 1,3,5-triaza-7-phosphaadamantane)) have been prepared. Values of IC₅₀ were calculated for the new platinum complexes 2 and 3 against a panel of human tumor cell lines representative of ovarian (A2780 and A2780cisR) and breast cancers (T47D). At 48 h incubation time complexes 2 and 3 show very low resistance factors (RF of < 2) against an A2780 cell line which has acquired resistant to cisplatin and were more active than cisplatin (about 4-fold for 3) in T47D (AR+, AR = androgen receptor). Compound 1 retains a moderate degree of relative binding affinity (RBA = 0.94%) for androgen receptors. The cytotoxicity of the non steroidal platinum analogues [Pt(dmba)Cl(L)] (dmba = dimethylbenzylamine; L = DMSO (4) and PTA (5)) has also been studied for comparison purposes. Theoretical calculations at the BP86/def2-TZVP level of theory on complex 3 have been undertaken.     

Synthesis, spectroscopical characterization and the biological activity in vitro of new platinum(II) complexes with imidazo[1,5-a]-1,3,5-triazine derivatives and dimethylsulfoxide

A series of platinum(II) complexes with 6,8-dimethylimidazo[1,5-a]-1,3,5-triazin-4(3H)-one (6,8-DiMe-4-O-IMT) (I) and 6,8-dimethyl-2-thioxo-2,3-dihydroimidazo[1,5-a]-1,3,5-triazin-4(1H)-one (6,8-DiMe-4-O-2-S-IMT) (II) of formula trans-[PtCl₂(dmso)(6,8-DiMe-4-O-IMT)] (1a) and trans-[PtCl₂(dmso)(6,8-DiMe-4-O-2-S-IMT)] (2a) have been prepared and characterized with ¹H, ¹³C, ¹⁵N, ¹⁹⁵Pt NMR and IR. Significant ¹⁵N NMR upfield coordination shifts (81-96 ppm) of N(7) atom indicate this nitrogen atom as a coordination site. The multinuclear NMR and IR spectra indicate the square planar geometry with N(7) bonded heterocycles, S-bonded dimethylsulfoxide and two trans chloride anions. The platinum(II) complexes were tested for their antiproliferative activity in vitro against the cells of four human cell lines: SW707 rectal adenocarcinoma, A549 non-small cell lung carcinoma, T47D breast cancer and HCV29T bladder cancer. The activity of (1a, 2a) was lower than that of cisplatin.     

Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity

[Pt(L)₂(ox)] (1), [Pt(2-OMeL)₂(ox)] (2), [Pt(3-OMeL)₂(ox)] (3), [Pt(2,3-diOMeL)₂(ox)] (4), [Pt(2,4-diOMeL)₂(ox)] (5), [Pt(3,4-diOMeL)₂(ox)] (6) and [Pt(3,5-diOMeL)₂(ox)]·4H₂O (7) platinum(II) oxalato (ox) complexes were synthesized using the reaction of potassium bis(oxalato)platinate(II) dihydrate with 2-chloro-N6-(benzyl)-9-isopropyladenine or its benzyl-substituted analogues (nL). The complexes 1-7, which represent the first platinum(II) oxalato complexes involving adenine-based ligands, were fully characterized by various physical methods including multinuclear and two dimensional NMR spectroscopy. A single-crystal X-ray analysis of [Pt(2,4-diOMeL)₂(ox)]·2DMF (5·2DMF; DMF = N,N′-dimethylformamide), proved the slightly distorted square-planar geometry in the vicinity of the Pt(II) ion with one bidentate-coordinated oxalate dianion and two adenine derivatives (nL) coordinated to the Pt(II) centre through the N7 atom of an adenine moiety, thereby giving a PtN₂O₂ donor set. In vitro cytotoxicity of the prepared complexes was tested by an MTT assay against osteosarcoma (HOS) and breast adenocarcinoma (MCF7) human cancer cell lines. The best results were achieved for the complexes 2 and 5 in the case of both cell lines, whose IC₅₀ values equalled 3.6 ± 1.0, and 4.3 ± 2.1 μM (for 2), and 5.4 ± 3.8, and 3.6 ± 2.1 μM (for 5), respectively. The IC₅₀ equals 9.2 ± 1.5 μM against MCF7 cells in the case of 1. The in vitro cytotoxicity of the mentioned complexes significantly exceeded commercially used platinum-based anticancer drugs cisplatin (34.2 ± 6.4 μM and 19.6 ± 4.3 μM) and oxaliplatin (> 50.0 μM for both cancer cell lines).